Zevra Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Zevra Therapeutics, Inc. (ZVRA) reported Net Income (Loss) Available to Common Stockholders, Basic of $8.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-05
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $8.39M, a 87.64% decline year-over-year.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $36.32M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $11.83M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$544.00K.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $77.58M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$105.51M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$46.05M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$26.77M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.39M 10-Q · filed 2026-08-05 | $44.72M 10-Q · filed 2026-08-05 | $56.54M derived: sum of 3 quarters · filed 2026-08-05 | $56.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $36.32M 10-Q · filed 2026-05-06 | $48.15M derived: sum of 2 quarters · filed 2026-05-06 | $47.60M derived: sum of 3 quarters · filed 2026-05-06 | $115.51M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.29M derived: sum of 2 quarters · filed 2026-03-09 | $79.19M derived: sum of 3 quarters · filed 2026-08-05 | $77.58M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$544.00K 10-Q · filed 2025-11-05 | $67.36M derived: sum of 2 quarters · filed 2026-08-05 | $65.75M 10-Q · filed 2025-11-05 | $28.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $67.91M 10-Q · filed 2026-08-05 | $65.06M 10-Q · filed 2026-08-05 | $29.07M derived: sum of 3 quarters · filed 2026-08-05 | -$4.15M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$3.10M 10-Q · filed 2026-05-06 | -$38.84M derived: sum of 2 quarters · filed 2026-05-06 | -$72.06M derived: sum of 3 quarters · filed 2026-05-06 | -$91.99M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$35.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$68.96M derived: sum of 2 quarters · filed 2026-03-09 | -$88.89M derived: sum of 3 quarters · filed 2026-03-09 | -$105.51M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$33.23M 10-Q · filed 2024-11-13 | -$53.15M derived: sum of 2 quarters · filed 2024-11-13 | -$69.77M 10-Q · filed 2024-11-13 | -$89.66M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2024-06-30 | -$19.93M 10-Q · filed 2024-08-14 | -$36.55M 10-Q · filed 2024-08-14 | -$56.44M derived: sum of 3 quarters · filed 2025-05-13 | -$66.81M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2024-03-31 | -$16.62M 10-Q · filed 2025-05-13 | -$36.51M derived: sum of 2 quarters · filed 2025-05-13 | -$46.88M derived: sum of 3 quarters · filed 2025-05-13 | -$49.45M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$19.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$30.26M derived: sum of 2 quarters · filed 2025-03-12 | -$32.83M derived: sum of 3 quarters · filed 2025-03-12 | -$46.05M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | -$10.37M 10-Q · filed 2024-11-13 | -$14.04M 10-Q · filed 2023-11-07 | -$12.94M derived: sum of 2 quarters · filed 2024-11-13 | -$26.16M 10-Q · filed 2024-11-13 | -$30.90M 10-Q · filed 2023-11-07 | -$20.41M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$2.57M 10-Q · filed 2024-08-14 | -$5.08M 10-Q · filed 2023-08-14 | -$15.79M 10-Q · filed 2024-08-14 | -$16.85M 10-Q · filed 2023-08-14 | -$10.04M derived: sum of 3 quarters · filed 2024-08-14 | -$16.66M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$13.22M 10-Q · filed 2024-05-09 | -$11.77M 10-Q · filed 2023-05-15 | -$7.47M derived: sum of 2 quarters · filed 2024-05-09 | -$14.08M derived: sum of 3 quarters · filed 2024-05-09 | -$38.13M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$866.00K derived: sum of 2 quarters · filed 2024-04-01 | -$24.91M derived: sum of 3 quarters · filed 2024-04-01 | -$26.77M 10-K · filed 2024-04-01 | -$41.54M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | -$6.62M 10-Q · filed 2023-11-07 | -$30.66M derived: sum of 2 quarters · filed 2023-11-07 | -$32.52M 10-Q · filed 2023-11-07 | -$35.23M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$24.04M 10-Q · filed 2023-08-14 | -$25.91M 10-Q · filed 2023-08-14 | -$28.61M derived: sum of 3 quarters · filed 2023-08-14 | -$30.37M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$1.86M 10-Q · filed 2023-05-15 | -$4.57M derived: sum of 2 quarters · filed 2023-05-15 | -$6.33M derived: sum of 3 quarters · filed 2023-05-15 | -$17.02M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$4.46M derived: sum of 2 quarters · filed 2023-03-07 | -$15.16M derived: sum of 3 quarters · filed 2023-03-07 | -$62.90M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | -$1.76M 10-Q · filed 2022-11-10 | -$12.45M derived: sum of 2 quarters · filed 2022-11-10 | -$60.19M 10-Q · filed 2022-11-10 | -$65.05M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$10.70M 10-Q · filed 2022-08-12 | -$58.44M 10-Q · filed 2022-08-12 | -$63.29M derived: sum of 3 quarters · filed 2022-08-12 | -$66.30M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$47.74M 10-Q · filed 2022-05-12 | -$52.60M derived: sum of 2 quarters · filed 2022-05-12 | -$55.60M derived: sum of 3 quarters · filed 2022-05-12 | -$54.75M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$7.87M derived: sum of 2 quarters · filed 2022-03-31 | -$7.01M derived: sum of 3 quarters · filed 2022-03-31 | -$12.76M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$3.01M 10-Q · filed 2021-11-10 | -$2.15M derived: sum of 2 quarters · filed 2021-11-10 | -$7.90M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $859.00K 10-Q · filed 2021-08-13 | $833.00K 10-Q · filed 2020-08-12 | -$4.89M 10-Q · filed 2021-08-13 | -$4.89M 10-Q · filed 2020-08-12 | ||||
| 2020-03-31 | -$5.75M 10-Q · filed 2021-05-14 | |||||||
| 2019-09-30 | $2.71M 10-Q · filed 2020-10-30 | |||||||
| 2018-06-30 | -$9.99M 10-Q · filed 2019-08-13 | |||||||
| 2016-06-30 | $8.63M 10-Q · filed 2017-08-10 | $6.04M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |